What’s in Spectrum Pharmaceuticals, Inc. (SPPI) After Today’s Big Increase?

April 17, 2018 - By Winifred Garcia

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 1.21, from 2.84 in 2017Q3. It worsened, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported.
Citigroup Incorporated reported 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Sector Pension Invest Board invested in 0.01% or 91,776 shares. Barclays Public Ltd Com holds 0.02% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 1.09 million shares. Clear Harbor Asset Mgmt Limited Liability Company accumulated 10,042 shares. Royal Natl Bank Of Canada stated it has 14,341 shares or 0% of all its holdings. Macquarie Grp holds 435,866 shares. Bnp Paribas Arbitrage Sa invested in 0% or 36,449 shares. Commercial Bank Of America De holds 415,652 shares or 0% of its portfolio. The Michigan-based Plante Moran Fincl Ltd has invested 0.09% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Consonance L P holds 12.64% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 7.38M shares. New York State Common Retirement Fund has 92,800 shares. Fincl Bank Of New York Mellon owns 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 1.05 million shares. State Board Of Administration Of Florida Retirement Sys holds 0% or 63,394 shares in its portfolio. One National Association has 0.03% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 21,210 shares. First Personal Financial has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 370 shares.

Since March 21, 2018, it had 0 insider purchases, and 13 selling transactions for $6.83 million activity. $78,884 worth of stock was sold by Turgeon Joseph W. on Wednesday, March 28. 2,640 shares were sold by GUSTAFSON KURT A, worth $47,868. On Wednesday, March 21 the insider Krassner Stuart Mitchell sold $78,278. 1,948 shares valued at $30,350 were sold by Riga Thomas J on Monday, April 2.

The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is a huge mover today! The stock increased 7.17% or $1.33 during the last trading session, reaching $19.89. About 1.69 million shares traded or 8.36% up from the average. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since April 17, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.
The move comes after 8 months positive chart setup for the $2.02B company. It was reported on Apr, 17 by Barchart.com. We have $21.48 PT which if reached, will make NASDAQ:SPPI worth $161.84M more.

Analysts await Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report earnings on May, 1. They expect $-0.31 EPS, down 72.22 % or $0.13 from last year’s $-0.18 per share. After $-0.29 actual EPS reported by Spectrum Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 6.90 % negative EPS growth.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 3 analysts covering Spectrum Pharmaceuticals (NASDAQ:SPPI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharmaceuticals had 4 analyst reports since October 24, 2017 according to SRatingsIntel. FBR Capital maintained the shares of SPPI in report on Tuesday, April 10 with “Buy” rating.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $2.02 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.